These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of infantile-onset LAL-D through the LSDP
- Drugs currently available for the treatment of infantile-onset LAL-D through the LSDP
- Treatment
- Dosage
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Guidelines
About this resource
Publication date:
Publication type:
Guideline
Language:
English